WO2017209070A1 - 吸収性物品 - Google Patents

吸収性物品 Download PDF

Info

Publication number
WO2017209070A1
WO2017209070A1 PCT/JP2017/019965 JP2017019965W WO2017209070A1 WO 2017209070 A1 WO2017209070 A1 WO 2017209070A1 JP 2017019965 W JP2017019965 W JP 2017019965W WO 2017209070 A1 WO2017209070 A1 WO 2017209070A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
absorbent
absorbent article
core
sheet
Prior art date
Application number
PCT/JP2017/019965
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
暁 湯山
祐一 廣瀬
義徳 村上
幸江 加藤
雅義 阿部
Original Assignee
花王株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 花王株式会社 filed Critical 花王株式会社
Priority to CN201780018704.3A priority Critical patent/CN108883002A/zh
Publication of WO2017209070A1 publication Critical patent/WO2017209070A1/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
    • A61F13/47—Sanitary towels, incontinence pads or napkins
    • A61F13/475—Sanitary towels, incontinence pads or napkins characterised by edge leakage prevention means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers
    • A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A61F13/531—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having a homogeneous composition through the thickness of the pad
    • A61F13/532—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having a homogeneous composition through the thickness of the pad inhomogeneous in the plane of the pad
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A61F13/534—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad
    • A61F13/535—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad inhomogeneous in the plane of the pad, e.g. core absorbent layers being of different sizes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A61F13/534—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad
    • A61F13/535—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad inhomogeneous in the plane of the pad, e.g. core absorbent layers being of different sizes
    • A61F13/536—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad inhomogeneous in the plane of the pad, e.g. core absorbent layers being of different sizes having discontinuous areas of compression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
    • A61F13/539—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium characterised by the connection of the absorbent layers with each other or with the outer layers

Definitions

  • the present invention relates to an absorbent article for menstrual blood absorption.
  • the surface sheet and the absorbent body are compressed and compressed on the surface of the surface sheet facing the wearer's skin.
  • Providing the formed leakage prevention groove is performed (for example, refer patent document 1).
  • Such a leak-proof groove is generally formed in an annular shape so as to surround the excretion spot part disposed opposite to the wearer's liquid excretion part when worn, or extends vertically on both the left and right sides of the excretion spot part. In any case, if a continuous leak-proof groove is formed, the rigidity of the absorbent article is increased and the fitting property is likely to be lowered.
  • Patent Document 2 discloses a menstrual band including an absorbent pad containing a salt of multivalent ions.
  • Patent Document 3 discloses a napkin containing a partially hydrated dicarboxylic anhydride copolymer or polycation as a blood gelling agent.
  • Patent Document 4 proposes a personal care absorbent article containing a triblock polymer or polycation containing polypropylene oxide and polyethylene oxide as a fluid treatment material.
  • the present applicant has previously proposed an absorbent article containing a blood coagulant containing a water-soluble metal compound in an absorbent core (see Patent Document 5).
  • JP 2010-148719 A Japanese Patent Publication No. 38-17449 JP-A-57-153648 Special table 2002-528232 gazette Japanese Patent Laying-Open No. 2005-287997
  • the present invention includes a liquid-permeable surface sheet that forms a skin-facing surface, a back sheet that forms a non-skin-facing surface, and an absorbent body disposed between the two sheets, and a longitudinal direction along the wearer's front-rear direction.
  • the present invention also provides an absorbent article for menstrual blood absorption having a transverse direction perpendicular to the longitudinal direction.
  • this invention has a side leak-proof groove in each of the both sides of the vertical direction center line in the said skin opposing surface, and this side leak-proof groove is a some short groove in which the said surface sheet sunk into the said absorber.
  • the absorbent article which has the structure arranged in the said longitudinal direction so that it may have a clearance gap between short grooves is provided.
  • the present invention includes a hemagglutinating agent in a lower member disposed closer to the back sheet than the top sheet, and the gap in the side leakage preventing groove or in the vicinity of the inner side in the lateral direction of the gap.
  • the present invention provides an absorbent article that overlaps with a portion of the lower member where the hemagglutinating agent is disposed.
  • FIG. 1 is a top view which looked at the sanitary napkin which is a 1st embodiment of the absorptive article of the present invention from the skin opposing surface side.
  • FIG. 2 is a schematic cross-sectional view taken along the line II-II in FIG. Fig.3 (a) and FIG.3 (b) are schematic top views which show the positional relationship of the leak-proof groove
  • FIG. 3C is a view corresponding to FIG. 3B in another embodiment.
  • FIG. 4: is the top view which looked at the sanitary napkin which is 2nd Embodiment of the absorbent article of this invention from the skin opposing surface side.
  • Patent Document 1 the end portion where the compressed groove is separated in the longitudinal direction is overlapped in the width direction, but in the separated portion, the absorbent article is easily broken at the portion when worn, and the excretion amount is large. Leakage is likely to occur.
  • Patent Documents 2 and 5 do not describe any structure for improving the blood absorption rate or improving the absorption amount, except that a water-soluble metal compound is used as the blood coagulant.
  • the absorbent article described in Patent Document 3 the embossed form is unclear and the blood gelling agent is concentrated along the end of the embossed wire or along the end thereof, so that an aggregate is formed in the part, Absorber absorption capacity cannot be fully utilized.
  • Patent Document 4 red blood cell clots are trapped between fibers of the nonwoven web, but it is difficult to guarantee blood absorption by the mechanism continuously.
  • Patent Document 3 and Patent Document 4 describe that fluid treatment agents containing polycations can be used for absorbent articles, only data on nonionic treatment materials are actually disclosed. Not. Further, in these techniques, the absorption of blood into the absorber is hindered by the decrease in liquid permeability due to blood aggregates in the portion of the absorbent article that faces the excretion spot of the wearer, and blood is absorbed. It is also disadvantageous in that it takes time and the amount of absorbed blood is reduced.
  • Patent Documents 1 to 5 describe nothing about using a blood modifying agent as a countermeasure against a decrease in leak-proof property that accompanies peeling between a surface sheet and an absorbent that occurs in a leak-proof groove. Not. Therefore, the subject of this invention is providing the absorbent article in which the improvement effect of the absorption performance by a hemagglutinating agent is expressed more effectively.
  • the problem of the present invention relates to providing an absorbent article that can solve the problems of the prior art.
  • a sanitary napkin 1 (hereinafter also referred to as “napkin 1”), which is a first embodiment of the present invention, is a liquid-permeable topsheet 2 that forms a skin-facing surface, as shown in FIGS.
  • a back sheet 3 forming a non-skin facing surface and a liquid retaining absorbent 4 disposed between both the sheets 2 and 3 are provided.
  • the top sheet 2, the absorber 4 and the back sheet 3 are integrated to form an absorbent main body 5.
  • Side leakproof sheets 6 are arranged on the surface sheet 2 side on both sides in the longitudinal direction of the absorbent main body 5.
  • the side leak-proof sheet 6 has a free end 61 that is not joined to the top sheet 2 and a fixed end 62 that is joined to the top sheet 2, and is used between the fixed end 62 and the free end 61 when used. Forms a leak-proof pocket (not shown) that separates from the top sheet 2 and prevents lateral leakage to the side.
  • a main body adhesive portion (not shown) used for fixing to the crotch portion of the shorts is provided on the non-skin facing surface of the absorbent main body 5.
  • the napkin 1 has a pair of wing portions 7 on both side portions in the longitudinal direction X. On the surface of the pair of wing portions 7 on the back sheet 3 side, a wing adhesive portion (not shown) used for fixing the crotch portion of the shorts to the non-skin facing surface is provided.
  • the top sheet 2, the back sheet 3, and the side leak-proof sheet 6, various kinds of materials conventionally used for absorbent articles such as sanitary napkins can be used without particular limitation.
  • the surface sheet 2 a single layer or multilayer nonwoven fabric, an apertured film, or the like can be used.
  • the surface sheet 2 may have irregularities having solid or hollow convex portions on the skin facing surface side, or may be adhered to the surface of the constituent fibers to the oil agent.
  • the back sheet 3 a resin film, a resin film, a nonwoven fabric, a laminated body, or the like can be used.
  • the back sheet 3 is liquid-impermeable (including liquid-impermeable) or water-repellent, and it is also preferable to use a moisture-permeable resin film or the like.
  • a laminated nonwoven fabric having a high water pressure resistance, a laminate of a resin film and a nonwoven fabric, or the like can be used.
  • the napkin 1 has a longitudinal direction X corresponding to the wearer's front-rear direction and a lateral direction Y orthogonal to the longitudinal direction X.
  • the napkin 1 includes an excretory part facing part B having an excretion spot part P disposed opposite to a wearer's liquid excretion part such as a vaginal opening in the longitudinal direction X and the lateral direction Y, and the excretion part facing part.
  • a front portion A disposed closer to the wearer's ventral side (front side) than B, and a rear portion C disposed closer to the wearer's back side (rear side) than the excretory portion facing portion B ing. That is, the napkin 1 is divided into the front part A, the excretion part opposing part B, and the rear part C in this order in the vertical direction X.
  • the skin-facing surface is a surface that faces the wearer's skin when the napkin 1 is worn in the napkin 1 or its constituent members (for example, the surface sheet 2 and the absorbent core 41).
  • the skin-facing surface is a surface of the napkin 1 or its constituent members that is directed to the side opposite to the skin side (usually the clothing side) when the napkin 1 is worn.
  • the excretion spot part P is a part that is disposed opposite to the liquid excretion part of the wearer when the absorbent article such as the napkin 1 is worn, and is directly supplied with menstrual blood. It is located at the center of the vertical direction X and the horizontal direction Y of B.
  • the excretory part-facing part B is the longitudinal direction of one wing part in the longitudinal direction X of the absorbent article when it has a so-called wing part like the napkin 1 of the present embodiment. It means a region sandwiched between the root along the direction X and the root along the vertical direction X of the other wing portion.
  • two folding lines that cross the absorbent article in the transverse direction Y which are generated when the absorbent article is folded into a tri-fold individual form.
  • region enclosed by the 1st folding line and the 2nd folding line is counted from the front end of the longitudinal direction X of this absorbent article.
  • the top sheet 2 covers the entire area of the skin 4 of the absorbent body 4, and the back sheet 3 covers the entire area of the non-skin facing surface of the absorbent body 4.
  • the surface sheet 2 and the back surface sheet 3 are joined to each other at the extended portions from both end edges in the longitudinal direction X of the absorber 4.
  • the back sheet 3 and the side leak-proof sheet 6 are joined to each other at portions extending outward in the lateral direction Y from both side edges along the longitudinal direction X of the absorber 4. In this way, the absorbent body 4 is sandwiched between the top sheet 2 and the back sheet 3.
  • any joining means such as an adhesive, heat sealing, ultrasonic sealing or the like is used.
  • the absorbent article of the present invention has side leakage preventing grooves on both sides of the longitudinal center line on the skin facing surface.
  • the napkin 1 according to the embodiment includes side leakage grooves 81 and 81 extending in the vertical direction X on both sides of the vertical center line CL on the skin facing surface of the napkin 1.
  • Each of the side leakage preventing grooves 81 has a configuration in which a plurality of short grooves 81a to 81c in which the topsheet 2 is inserted into the absorber 4 are arranged in the longitudinal direction Y so as to have a gap 81d between the short grooves. have.
  • the pair of side leak-proof grooves 81, 81, the front leak-proof groove 82, and the rear leak-proof groove 83 form an annular leak-proof groove 8 composed of a plurality of intermittent leak-proof grooves.
  • the annular leak-proof groove 8 is formed so as to surround the excretion spot portion P.
  • Each of the pair of side leakage preventing grooves 81 extends in the longitudinal direction X of the napkin 1 on each side of the excretion spot portion P in the lateral direction Y.
  • the pair of side leakage preventing grooves 81 and 81 preferably extend in the longitudinal direction X at least on both sides of the excretion part facing part B with the excretion spot part P interposed therebetween.
  • the side leakage prevention grooves 81 preferably extend from the excretory part facing part B to the front part A or the rear part C. As shown in FIG. 1, the front part A and the excretion part facing part B are provided. And it is more preferable that each extends over the rear part C.
  • the side leak-proof grooves 81 in the present embodiment are positioned as a plurality of short grooves 81a to 81c in the excretory part facing part B, preferably at portions located on both sides in the lateral direction Y across the excretion spot part P.
  • the short grooves adjacent to each other in the longitudinal direction X that is, the front short groove 81a and the central short groove 81b, and the central short groove 81b and the rear short groove 81c have a gap 81d.
  • the distance W between the two points P1 and P2 at which the distance between the short grooves is minimum is the flexibility of the absorbent article.
  • it is preferably 0.5 mm or more, more preferably 1 mm or more, and from the viewpoint of improving leakage prevention, it is preferably 10 mm or less, more preferably 8 mm or less, and flexibility.
  • it is preferably 0.5 mm or more and 10 mm or less, more preferably 1 mm or more and 8 mm or less.
  • the skin facing surface side of the absorbent body 4 is recessed into a groove shape together with the surface sheet 2.
  • the portions where the grooves 81a to 81c, 82, 83 are formed are portions of the absorber 4 that are located on both sides of the grooves 81a to 81c, 82, 83, respectively.
  • the short grooves 81a to 81c, the front leakage prevention groove 82, and the rear leakage prevention groove 83 that constitute the side leakage prevention groove 81 are, for example, pressurized against a stack of the top sheet 2 and the absorbent body 4, or It can be formed by embossing with heating and pressurization.
  • the main role of each of the leak-proof grooves 81 to 83 is to suppress the diffusion of liquid in the planar direction of the napkin 1.
  • the absorbent body 4 of the napkin 1 has an absorbent core 41 containing pulp fibers and a core wrap sheet 42 that covers the absorbent core 41.
  • the core wrap sheet 42 in this embodiment is wound down to the skin-side portion 42 a that covers the skin-facing surface side of the absorbent core 41 and the non-skin-facing surface side of the absorbent core 41.
  • seat 42 has the overlapping part 42c of the sheets in the non-skin part 42b.
  • the core wrap sheet covering the absorbent core 41 may wrap the entire absorbent core 41 with a single sheet, or may wrap the entire absorbent core 41 with two or more sheets.
  • the skin facing surface side and the non-skin facing surface side of the absorbent core 41 may be covered with separate sheets.
  • the core wrap sheet covering the skin facing surface side of the absorbent core 41 is defined as the skin side core wrap sheet 42a and the non-absorbing core 41 non-covered.
  • a portion covering the skin facing surface side is also referred to as a non-skin side core wrap sheet 42b.
  • the circular portion indicated by reference numeral 9 of the skin side portion (skin side core wrap sheet) 42a covering the skin facing surface side of the absorbent core 41 is a hemagglutinating agent. It becomes the flocculant arrangement
  • the skin-side core wrap sheet 42 a is one of the lower members disposed in a position closer to the back sheet 3 than the top sheet 2 in the thickness direction of the napkin 1.
  • the napkin 1 has a skin-side core wrap sheet 42a, an absorbent core 41, and a non-skin-side core wrap sheet 42b as lower members.
  • the flocculant arrangement part 9 containing a hemagglutinating agent is formed at least on the skin-side core wrap sheet 42a which is a lower member adjacent to the top sheet 2 in the thickness direction of the absorbent article.
  • the flocculant disposition part 9 containing the hemagglutinating agent may be formed only on the skin-side core wrap sheet 42a, but is preferably formed on the skin-side core wrap sheet 42a and the absorbent core 41. It is more preferable that the side core wrap sheet 42a, the absorbent core 41, and the non-skin side core wrap sheet 42b are formed.
  • the aggregating agent disposition portion 9 containing a hemagglutinating agent is adjacent to the non-skin facing surface of the topsheet 2 regardless of the configuration of the absorber 4 and whether there is a second sheet between the topsheet 2 and the absorber 4. It is preferable that it extends over all lower members from the member to the member adjacent to the skin facing surface of the back sheet 3. In any of these embodiments, the aggregating agent disposition portion 9 is “a portion where the hemagglutinating agent is disposed in the lower member”.
  • FIG. 4 is a schematic plan view showing a positional relationship with a flocculant arrangement unit 9.
  • the gap 81d between the short grooves in each side leakage prevention groove 81 and the inner side in the lateral direction of the gap 81d are the skin-side core wrap. It overlaps with the flocculant arrangement portion 9 formed on the lower member such as the sheet 42a.
  • the expression “the gap or the vicinity in the lateral direction of the gap overlaps with the flocculant arrangement portion 9” includes the case where only the gap 81d overlaps the flocculant arrangement portion 9 and the case where the gap 81d
  • the gap 81d overlaps the flocculant arrangement portion 9
  • the expression “the gap or the vicinity in the lateral direction of the gap overlaps with the flocculant arrangement portion 9” includes the case where only the gap 81d overlaps the flocculant arrangement portion 9 and the case where the gap 81d
  • FIG. 3B shows a portion of the short groove forming the side leakage preventing groove 81 that overlaps the flocculant arrangement portion 9 indicated by reference numeral S among the plural flocculant arrangement portions 9 shown in FIG. Indicates.
  • the vicinity of the inner side in the lateral direction Y of the gap 81d includes the vicinity N of the end c on the inflow side into which the menstrual blood supplied to the excretion spot portion P flows in the gap 81d, as shown in FIG. It is preferable from the viewpoint of improving leakage prevention.
  • the shortest horizontal distance from the end c on the inflow side of the gap 81d to the flocculant arrangement portion 9 is preferably 0 mm or more and 5 mm or less, more preferably 0 mm or more and 3 mm. It is as follows.
  • FIG. 3C shows another example in which the vicinity in the lateral direction Y of the gap 81d includes the vicinity N of the end c on the inflow side of the gap 81d.
  • the left side is the vertical center line side close to the excretion spot part P
  • the right side is the side far from the excretion spot part P.
  • the distance W between the two points P1 and P2 at which the distance between the short grooves is minimum is the flexibility of the absorbent article.
  • the thickness is preferably 0.5 mm or more, more preferably 1 mm or more, and from the viewpoint of improving leakage prevention, it is preferably 10 mm or less, more preferably 8 mm or less. From the standpoint of achieving both compatibility and leakage prevention properties, it is preferably 0.5 mm or more and 10 mm or less, more preferably 1 mm or more and 8 mm or less.
  • the side leakage grooves 81 are provided between the front short groove 81a and the front leakage prevention groove 82 and between the rear short groove 81c and the rear leakage prevention groove 83, respectively.
  • a gap 81e similar to the gap 81d between the short grooves to be formed is formed, and the gap 81e and the vicinity of the inside of the gap 81e in the width direction are also formed on the lower member such as the skin-side core wrap sheet 42a. It overlaps with the placement unit 9.
  • FIG. 4 is a plan view showing a sanitary napkin 1A (hereinafter also referred to as “napkin 1A”) according to a second embodiment of the present invention, in which the aggregating agent arranging portion 9A in the lower member such as the skin-side core wrap sheet 42a, 9A is also shown.
  • a pair of strip-shaped flocculant arrangement portions 9A and 9A are respectively provided on both sides of the longitudinal center line CL of the absorbent article in the lower member such as the skin-side core wrap sheet 42a. It extends in the longitudinal direction X.
  • each of the pair of side leakage preventing grooves 81 includes a front short groove 81a, a central short groove 81b, and a rear short groove 81c.
  • the gap 81d between the short grooves adjacent to each other in the vertical direction X and the inner side vicinity in the horizontal direction of the gap 81d overlap with the flocculant arrangement portion 9A.
  • the core wrap sheet is used for the purpose of improving the shape retention of the absorbent core, which is insufficient in shape retention by itself, or preventing leakage of the constituent material of the absorbent core.
  • the fiber sheet is used.
  • the cellulosic fibers constituting the thin paper include wood pulp fibers, rayon fibers, cotton fibers, and cellulose acetate fibers.
  • cellulosic fiber pulp include wood pulp such as softwood kraft pulp or hardwood kraft pulp, and non-wood pulp such as cotton pulp or straw pulp. These cellulosic fibers can be used singly or in combination of two or more. Further, from the viewpoint of improving the strength, a small amount of non-cellulosic fibers can be mixed.
  • non-cellulosic fibers examples include polyolefin fibers such as polyethylene and polypropylene, and condensation fibers such as polyester and polyamide.
  • the proportion of the cellulosic fibers in the constituent fibers of the thin paper is preferably 70% by mass to 100% by mass, more preferably 90% by mass to 100% by mass, and still more preferably 100% by mass.
  • a nonwoven fabric can also be used as the core wrap sheet. As the nonwoven fabric used for the core wrap sheet, nonwoven fabrics produced by various production methods can be used without any particular limitation.
  • Spunlace nonwoven fabric, air-through nonwoven fabric which is a nonwoven fabric obtained by heat-sealing the constituent fibers of the fiber web by hot air treatment, resin bond nonwoven fabric which is a nonwoven fabric obtained by adhering the constituent fibers of the fiber web with an adhesive, etc. can be mentioned.
  • the fiber web of spunlace nonwoven fabric, air-through nonwoven fabric, and resin bond nonwoven fabric can be manufactured by a card machine or an airlaid method in which fibers are stacked in air.
  • Non-woven fabric fibers are made from cellulose-based hydrophilic fibers such as wood pulp fibers, rayon fibers, cotton fibers and cellulose acetate, polyolefins such as polyethylene and polypropylene, polyesters such as polyethylene terephthalate, and synthetic resins such as polyamides such as nylon.
  • the synthetic fiber which becomes is mentioned.
  • As the synthetic fiber a core-sheath type or side-by-side type composite fiber may be used. Among these, for the same reason as using thin paper, when any of the above-mentioned nonwoven fabric manufacturing methods is adopted, it is preferable that the raw material fibers are cellulosic fibers.
  • the proportion of the cellulosic fibers in the constituent fibers of the nonwoven fabric is preferably 70% by mass to 100% by mass, more preferably 90% by mass to 100% by mass, and still more preferably 100% by mass.
  • the raw material fiber of a nonwoven fabric can be used individually by 1 type or in combination of 2 or more types.
  • the absorptive core 41 of the napkin 1 of this embodiment is composed of a mixed product of pulp fibers and a superabsorbent polymer.
  • the mixed fiber stack is manufactured by a known drum-type fiber stacking apparatus including a stacking drum having a stacking concave portion on the peripheral surface, and is sucked from the bottom surface of the stacking concave portion, The surface is supplied with pulp fibers and superabsorbent polymer as the absorbent core forming material in a scattered state, and after the absorbent core forming material is deposited in the accumulation recess, it is released from the accumulation recess. Is obtained.
  • the absorbent core 41 of the napkin 1 of the present embodiment may be a single fiber stack of pulp fibers that does not contain a superabsorbent polymer.
  • Examples of the pulp fibers constituting the absorbent core 41 include cellulose-based hydrophilic fibers such as wood pulp fibers, rayon fibers, cotton fibers, and cellulose acetate. These fibers can be used alone or in combination of two or more.
  • Examples of the raw material pulp of the pulp fiber include wood pulp such as softwood kraft pulp or hardwood kraft pulp, and non-wood pulp such as cotton pulp or wall pulp.
  • the absorbent core 41 is made of synthetic fibers such as polyolefin fibers such as polyethylene and polypropylene, condensed fibers such as polyester and polyamide, in addition to pulp fibers made of cellulosic hydrophilic fibers. A small amount may be mixed.
  • the absorbent core in the present invention has a ratio of pulp fibers (cellulosic fibers), particularly wood pulp fibers, of preferably 70% by mass or more and 100% by mass or less, more preferably 90% by mass or more and 100% by mass or less. Preferably it is 100 mass%.
  • the absorbent core 41 may contain a water-absorbing polymer.
  • a particulate polymer is generally used, but a fibrous polymer may be used.
  • the shape thereof may be any of a spherical shape, a block shape, a bowl shape, and an amorphous shape.
  • a polymer or copolymer of acrylic acid or an alkali metal acrylate can be used. Examples thereof include polyacrylic acid and salts thereof and polymethacrylic acid and salts thereof.
  • sodium salts can be preferably used.
  • a copolymer obtained by copolymerizing the above-mentioned comonomer within a range that does not deteriorate the performance of the superabsorbent polymer.
  • a large amount of excrement such as blood can be quickly absorbed and retained more stably.
  • the method for forming the agglutinating agent placement portion by containing a hemagglutinating agent in a napkin component such as the core wrap sheet 42 is not particularly limited as long as the hemagglutinating agent can be retained in the component.
  • the agent can be dissolved in an appropriate solvent such as water or ethanol, and the solution can be adhered to a desired part of the constituent member and then dried to remove the solvent, thereby effectively attaching the hemagglutinating agent to the core wrap sheet 42. From the viewpoint of making it.
  • As a method for adhering the solution to the constituent member dropping of the solution onto a predetermined portion of the constituent member and various coating methods can be employed.
  • liquid coating to the predetermined location of the structural member using well-known liquid coating apparatuses such as a spray method, a dipping method, a transfer method, die coating, gravure coating, an inkjet method, screen printing, etc. are mentioned.
  • the drying may be any of drying by heating, drying by reduced pressure, and drying combining heating and reduced pressure, but natural drying may be used instead of these forced drying.
  • the napkins 1 and 1A of the first and second embodiments are used by being fixed to the crotch part of the shorts or the like with an adhesive part provided on the non-skin facing surface of the napkin 1 in the same manner as a normal sanitary napkin.
  • the side leakage prevention groove 81 is constituted by a plurality of short grooves 81a to 81c having a shorter length instead of one continuous leakage prevention groove. Since the side leakage prevention groove 8 can be bent at the gap 81d between the adjacent short grooves in the longitudinal direction X, the napkins 1 and 1A are excellent in flexibility.
  • the menstrual blood is excreted in the excretion spot portion P during wearing, and the menstrual blood diffuses in the horizontal direction and reaches the gap 81d between the short grooves in the side leakage preventing groove 8,
  • the hemagglutinating agent disposed in the vicinity of the gap 81d or the laterally inner side of the gap 81d located in front of the gap 81d acts on the menstrual blood, and the red blood cell aggregate 16 is formed in the menstrual blood.
  • the blood 11 is prevented from diffusing from the inside to the outside of the side leakage preventing groove 81 through the gap 81d between the short grooves. This prevents leakage such as side leakage.
  • the menstrual component diffuses in the vertical direction, wraps around the front leakage prevention groove 82 and the rear leakage prevention groove 83, and reaches the gap 81e between the short grooves, the lateral direction of the gap 81e
  • the hemagglutinating agent disposed in the vicinity of the inner side of the blood cell acts on the menstrual blood and generates an agglomerate 16 of red blood cells, so that the menstrual blood 11 passes through the short groove 81e from the inside of the side leakage preventing groove 81. Leak-proof performance is maintained by suppressing diffusion to the outside.
  • the napkins 1 and 1A of the first and second embodiments are excellent in both flexibility and leakage prevention performance. Further, in the leak-proof groove 8 formed by pressurizing and compressing the topsheet 2 and the absorber 4 integrally, even when a gap is generated between the topsheet 2 and the absorber 4, the same applies. Furthermore, the hemagglutinating agent contained in the lower member such as the skin-side core wrap sheet 42 acts on menstrual blood that has entered the gap between the top sheet 2 and the absorbent body 4, and absorption in or near the gap is performed.
  • the flocculant arrangement portion 9 or 9A preferably satisfies any one or more of the following conditions (1) to (3).
  • the abundance per unit area of the hemagglutinating agent is 6 g / m 2 or more in the overlapping portion overlapping the side leakage prevention groove 81 extending in the longitudinal direction X of the leakage prevention groove 8. 80 g / m 2 or less, more preferably 12 g / m 2 or more and 70 g / m 2 or less.
  • the amount of hemagglutinating agent is the pure amount of the cationic polymer when the hemagglutinating agent is a cationic polymer, and the amount per unit area of the hemagglutinating agent is measured as follows. Is done. [Method for measuring the amount of hemagglutinating agent present per unit area] After the solution in which the cationic polymer is dissolved is applied to the lower member, the lower member is left to stand for 2 hours at 30 ° C. and 10% RH to be dried.
  • the flocculant arrangement part is cut out from the lower member, the area and weight thereof are measured, and the weight of the lower member having the same size as the cut out flocculant arrangement part is subtracted from the measured weight, so that the cation in the flocculant arrangement part
  • the abundance of the hemagglutinating agent per unit area is calculated by calculating the weight of the functional polymer and dividing it by the area of the aggregating agent disposition portion.
  • the hemagglutinating agent is not disposed in the central portion in the horizontal direction, for example, the excretion spot portion P, the hemagglutinating agent is disposed in a portion overlapping with the gap 81d between the short grooves constituting the side leakage preventing grooves 81.
  • the hemagglutinating agent is disposed in a portion overlapping with the gap 81d between the short grooves constituting the side leakage preventing grooves 81.
  • the cationic polymer used as the hemagglutinating agent preferably has a molecular weight of 2000 or more, more preferably 10,000 or more, and even more preferably 150,000 or more.
  • the upper limit of the molecular weight is preferably 30 million or less, more preferably 22 million or less, and even more preferably 10 million or less. Also, it is preferably 2000 or more and 30 million or less, more preferably 10,000 or more and 22 million or less, and further preferably 150,000 or more and 10 million or less.
  • the top sheet 2 of the napkin 1, 1A is preferably hydrophilic as a whole, and at least a portion overlapping with the flocculant arrangement portions 9, 9A and the leakage prevention groove 8, particularly the side leakage prevention groove 81 is present. It is preferably hydrophilic.
  • the topsheet 2 is hydrophilic, when the menstrual blood that is hydrophilic diffuses in the absorbent body, it diffuses efficiently even in the side leakage prevention groove 81 that overlaps a part or the whole of the flocculant arrangement portion 9. I can do it.
  • a nonwoven fabric or polyethylene which is mainly composed of cellulose fibers such as wood pulp fibers, rayon fibers, cotton fibers, cellulose acetate fibers, etc., as the topsheet 2
  • a method using a non-woven fabric or the like mainly composed of fibers obtained by hydrophilizing synthetic fibers such as polyolefin fibers such as polypropylene and condensed fibers such as polyester and polyamide with a hydrophilic oil a nonwoven fabric or polyethylene, which is mainly composed of cellulose fibers such as wood pulp fibers, rayon fibers, cotton fibers, cellulose acetate fibers, etc.
  • a method using a non-woven fabric or the like mainly composed of fibers obtained by hydrophilizing synthetic fibers such as polyolefin fibers such as polypropylene and condensed fibers such as polyester and polyamide with a hydrophilic oil.
  • the short groove in the absorbent article of the present invention may be linear in a plan view, but is preferably non-linear as in the napkins 1 and 1A of the first and second embodiments.
  • the front short groove 81a and the rear short groove 81c are directed inward in the lateral direction Y as shown in FIG.
  • a curved portion b curved in a convex shape toward the outer side in the lateral direction Y, and the central short groove 81b is formed outward in the lateral direction Y.
  • one curved portion b that is curved in a convex shape toward the front and two curved portions a that are located in front of and behind the curved portion b and are curved in a convex shape toward the inside in the lateral direction Y. Having one curved portion that curves convex outwardly causes the napkin to protrude toward the wearer's skin when an external force is applied from the left and right in the lateral direction Y toward the center of the wing portion of the napkin. Therefore, the external force is dispersed, and the external force applied to the side leakage preventing groove 81 is reduced.
  • the degree and frequency of occurrence of separation of the topsheet from the absorbent body in the side leakage preventing groove 81 and the gap generated in the pressure compression section of the absorbent body are reduced. Therefore, it is preferable from the viewpoints such as prevention of liquid movement by the leak-proof groove and further improvement of the leak-proof performance of the absorbent article. Further, since the short grooves 81a to 81c constituting the side leakage preventing groove 81 are non-linear, the side leakage preventing groove 81 is more easily bent, and the short grooves 81a to 81c are formed in the lateral direction.
  • the side leakage preventing groove 81 is more easily bent.
  • the flexibility of the lower member may be reduced depending on the type, amount of application, and the like. If the side leak-proof groove 81 is non-linear, more preferably non-linear having one or more curved portions a and b, the napkins 1 and 1A are more easily bent, and the lower member is formed of a hemagglutinating agent. An effect of improving flexibility that is sufficiently greater than the effect of curing is obtained.
  • Red blood cells aggregated by the hemagglutinating agent become aggregates.
  • a cationic polymer is useful as the hemagglutinating agent.
  • the reason is as follows. Red blood cells have a red blood cell membrane on their surface.
  • the erythrocyte membrane has a two-layer structure. This two-layer structure is composed of a red blood cell membrane skeleton as a lower layer and a lipid membrane as an upper layer.
  • the lipid film exposed on the surface of erythrocytes contains a protein called glycophorin.
  • Glycophorin has a sugar chain to which a sugar having an anionic charge called sialic acid is bonded at its end.
  • erythrocytes can be treated as colloidal particles having an anionic charge.
  • an aggregating agent is used for aggregating the colloidal particles.
  • erythrocytes are anionic colloidal particles, it is advantageous to use a cationic substance as an aggregating agent from the viewpoint of neutralizing the electric double layer of erythrocytes.
  • the aggregating agent has a polymer chain, the polymer chains of the aggregating agent adsorbed on the surface of the erythrocyte tend to be entangled with each other, thereby promoting the aggregation of erythrocytes.
  • the aggregating agent has a functional group
  • the hemagglutinating agent cationic polymer
  • Preferred hemagglutinating agents used in the present invention are those that aggregate red blood cells in blood to form aggregates, and preferably act to separate the formed red blood cell aggregates and plasma components.
  • a particularly preferred hemagglutinating agent has the property that, when 1000 ppm of a measurement sample agent is added to simulated blood, at least two or more red blood cells aggregate to form an aggregate while maintaining the fluidity of blood. Is.
  • the above-mentioned “state in which the fluidity of blood is maintained” means that 10 g of simulated blood to which a measurement sample agent is added 1000 ppm is screw tube bottle (manufactured by Maruemu, product number “screw tube No. 4”, mouth inner diameter 14.5 mm, body When the screw tube bottle containing the simulated blood is turned 180 degrees, the pseudo blood of 80% or more flows down within 5 seconds.
  • Simulated blood means that the viscosity measured using a B-type viscometer (model number TVB-10M manufactured by Toki Sangyo Co., Ltd., measurement conditions: rotor No. 19, 30 rpm, 25 ° C., 60 seconds) is 8 mPa ⁇ s.
  • the blood cell / plasma ratio of defibrinated horse blood was prepared.
  • erythrocytes aggregate to form an aggregate is determined as follows. That is, simulated blood to which a measurement sample agent was added at 1000 ppm was diluted 4000 times with physiological saline, and a laser diffraction / scattering type particle size distribution measuring device (manufactured by HORIBA, model number: LA-950V2, measurement condition: flow cell measurement). When the median diameter of volume average particle diameter measured at a temperature of 25 ° C. is 10 ⁇ m or more by a laser diffraction scattering method using a circulation speed of 1 and no ultrasound, “two or more red blood cells are aggregated. It is determined that an aggregate is formed.
  • the hemagglutinating agent used in the present invention satisfies the above-mentioned properties by a single compound that meets the above-described properties, a plurality of combinations of single compounds that meet the above-mentioned properties, or a combination of a plurality of compounds (aggregation of erythrocytes). Agent).
  • the hemagglutinating agent is an agent limited to those having an erythrocyte aggregating action as defined above. Therefore, when the hemagglutinating agent contains a third component that does not meet the above definition, it is expressed as a hemagglutinating agent composition and is distinguished from the hemagglutinating agent.
  • the hemagglutinating agent used in the present invention those containing a cationic polymer are preferable.
  • the cationic polymer include cationized cellulose and cationized starch such as hydroxypropyltrimonium chloride.
  • the hemagglutinating agent used in the present invention can also contain a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate as a cationic polymer.
  • the “quaternary ammonium salt” includes a compound having a plus monovalent charge at the nitrogen atom position, or a compound that generates a plus monovalent charge at the nitrogen atom position by neutralization.
  • the “copolymer” is a polymer obtained by copolymerization of two or more kinds of polymerizable monomers, and is a binary copolymer or a ternary copolymer or more. Includes both things.
  • the “polycondensate” is a polycondensate obtained by polymerizing a condensate composed of two or more monomers.
  • the hemagglutinating agent used in the present invention contains a quaternary ammonium salt homopolymer and / or a quaternary ammonium salt copolymer and / or a quaternary ammonium salt polycondensate as the cationic polymer
  • the hemagglutination The agent may contain any one of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer and a quaternary ammonium salt polycondensate, or any combination of two or more. May be included.
  • a quaternary ammonium salt homopolymer can be used individually by 1 type or in combination of 2 or more types.
  • the quaternary ammonium salt copolymer can be used alone or in combination of two or more.
  • a quaternary ammonium salt polycondensate can be used individually by 1 type or in combination of 2 or more types.
  • the “hemagglutinating agent” refers to the aggregation of erythrocytes by a single compound or a combination of single compounds capable of aggregating blood erythrocytes or a combination of a plurality of compounds. It is an agent that expresses. That is, the hemagglutinating agent is an agent limited to those having a hemagglutination effect.
  • the hemagglutinating agent contains the third component, it is expressed as a hemagglutinating agent composition and is distinguished from the hemagglutinating agent.
  • the term “single compound” is a concept including compounds having the same composition formula but having different molecular weights due to different numbers of repeating units.
  • quaternary ammonium salt polymer a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate from the viewpoint of adsorptivity to erythrocytes. preferable.
  • the quaternary ammonium salt homopolymer, the quaternary ammonium salt copolymer and the quaternary ammonium salt polycondensate are collectively referred to as “quaternary ammonium salt polymer”.
  • the quaternary ammonium salt homopolymer is obtained by polymerizing one type of polymerizable monomer having a quaternary ammonium moiety.
  • the quaternary ammonium salt copolymer uses at least one polymerizable monomer having a quaternary ammonium moiety and, if necessary, at least one polymerizable monomer having no quaternary ammonium moiety. It was obtained by using seeds and copolymerizing them. That is, the quaternary ammonium salt copolymer is obtained by using two or more polymerizable monomers having a quaternary ammonium moiety and copolymerizing them, or having a quaternary ammonium moiety.
  • the quaternary ammonium salt copolymer may be a random copolymer, an alternating copolymer, a block copolymer, or a graft copolymer.
  • the quaternary ammonium salt polycondensate is obtained by polymerizing these condensates using a condensate composed of one or more monomers having a quaternary ammonium moiety.
  • the quaternary ammonium salt polycondensate is obtained by polymerizing two or more condensates having two or more monomers having a quaternary ammonium moiety, or the quaternary ammonium moiety. And a condensate comprising one or more monomers having quaternary ammonium moieties and one or more monomers having no quaternary ammonium moiety, and obtained by condensation polymerization.
  • the quaternary ammonium salt polymer is a cationic polymer having a quaternary ammonium moiety.
  • a quaternary ammonium moiety can be generated by quaternary ammoniumation of a tertiary amine using an alkylating agent.
  • the tertiary amine can be dissolved in acid or water and generated by neutralization. Or it can produce
  • the alkylating agent include alkyl halides and dialkyl sulfates such as dimethyl sulfate and dimethyl sulfate.
  • dialkyl sulfate is preferable because the problem of corrosion that may occur when an alkyl halide is used does not occur.
  • the acid include hydrochloric acid, sulfuric acid, nitric acid, acetic acid, citric acid, phosphoric acid, fluorosulfonic acid, boric acid, chromic acid, lactic acid, oxalic acid, tartaric acid, gluconic acid, formic acid, ascorbic acid, and hyaluronic acid. .
  • a quaternary ammonium salt polymer in which a tertiary amine moiety is quaternized with an alkylating agent, because the electric double layer of erythrocytes can be reliably neutralized.
  • Quaternary ammoniumation by a nucleophilic reaction including a condensation reaction can be caused by a ring-opening polycondensation reaction of dimethylamine and epichlorohydrin or a cyclization reaction of dicyandiamide and diethylenetriamine.
  • Red blood cells have a red blood cell membrane on their surface.
  • the erythrocyte membrane has a two-layer structure. This two-layer structure is composed of a red blood cell membrane skeleton as a lower layer and a lipid membrane as an upper layer.
  • the lipid film exposed on the surface of erythrocytes contains a protein called glycophorin.
  • Glycophorin has a sugar chain to which a sugar having an anionic charge called sialic acid is bonded at its end.
  • erythrocytes can be treated as colloidal particles having an anionic charge.
  • an aggregating agent is used for aggregating the colloidal particles.
  • erythrocytes are anionic colloidal particles, it is advantageous to use a cationic substance as an aggregating agent from the viewpoint of neutralizing the electric double layer of erythrocytes.
  • the aggregating agent has a polymer chain, the polymer chains of the aggregating agent adsorbed on the surface of the erythrocyte tend to be entangled with each other, thereby promoting the aggregation of erythrocytes.
  • the aggregating agent has a functional group, it is preferable because the aggregation of erythrocytes is promoted by the interaction between the functional groups.
  • the cationic polymer used as the hemagglutinating agent has a molecular weight of preferably 2000 or more, more preferably 10,000 or more, from the viewpoint of effectively producing red blood cell aggregates. More preferably, it is 10,000 or more.
  • the molecular weight of the cationic polymer is higher than these values, the cationic polymer is sufficiently entangled between erythrocytes and the cationic polymer is crosslinked between erythrocytes, and menstrual blood has an effect on red blood cell aggregates. It is more preferable because the effect of suppressing the diffusion of blood is enhanced.
  • the upper limit of the molecular weight is preferably 30 million or less, more preferably 22 million or less, and even more preferably 10 million or less.
  • the cationic polymer dissolves well into menstrual blood.
  • the molecular weight of the cationic polymer is such that menstrual blood is separated into red blood cells and plasma, effectively forming red blood cell aggregates, and plasma is efficiently absorbed by superabsorbent polymers, increasing the amount of absorption and absorption rate, and preventing leakage. From the viewpoint of suppressing the movement of menstrual blood from the inside to the outside of the groove and maintaining good leakage prevention performance, it is preferably from 20 to 30 million, more preferably from 10,000 to 22 million. More preferably, it is 150,000 to 10,000,000.
  • the molecular weight of the cationic polymer can be controlled by appropriately selecting the polymerization conditions.
  • cationic polymers of different molecular weight within the above-mentioned molecular weight range.
  • the molecular weight of the cationic polymer can be measured using HLC-8320GPC manufactured by Tosoh Corporation. Specific measurement conditions are as follows.
  • the molecular weight said to this invention is a weight average molecular weight.
  • a column in which a guard column ⁇ manufactured by Tosoh Corporation and an analytical column ⁇ -M are connected in series is used at a column temperature of 40 ° C.
  • the detector uses RI (refractive index).
  • 1 mg of the treatment agent (quaternary ammonium salt polymer) to be measured is dissolved in 1 mL of the eluent.
  • a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate uses an eluent in which 150 mmol / L sodium sulfate and 1% by mass acetic acid are dissolved in water.
  • a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate has a molecular weight of 5900, a pullulan with a molecular weight of 47300, a pullulan with a molecular weight of 212,000, and a molecular weight of 788,000 with respect to 10 mL of the eluent. Pullulan, a pullulan mixture with 2.5 mg each dissolved, is used as the molecular weight standard.
  • a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate is measured at a flow rate of 1.0 mL / min and an injection amount of 100 ⁇ L.
  • Polyethylene oxide (PEO) having a molecular weight of 50,000, PEO having a molecular weight of 235,000, PEO having a molecular weight of 875,000, and a PEG-PEO mixture in which 10 mg of each is dissolved is used as a molecular weight standard. Except for a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, the flow rate is 0.6 mL / min and the injection amount is 100 ⁇ L.
  • the cationic polymer is preferably water-soluble.
  • water-soluble means that 0.05 g of a 1 mm or less powdery or 0.5 mm or less film-like cationic polymer is added to a 100 mL glass beaker (5 mm ⁇ ) and mixed with 50 mL ion-exchanged water at 25 ° C.
  • a stirrer chip having a length of 20 mm and a width of 7 mm is inserted, and the whole amount is dissolved in water within 24 hours under stirring at 600 rpm using a magnetic stirrer HPS-100 manufactured by ASONE Co., Ltd.
  • the total amount is preferably dissolved in water within 3 hours, and the total amount is more preferably dissolved in water within 30 minutes.
  • the cationic polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto.
  • the quaternary ammonium salt polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto.
  • the quaternary ammonium moiety is preferably present in the side chain.
  • the main chain and the side chain are bonded at one point, the flexibility of the side chain is difficult to be hindered, and the quaternary ammonium moiety present in the side chain is smoothly formed on the surface of the erythrocyte. Adsorbs.
  • bonded at one point means that one of the carbon atoms constituting the main chain is single-bonded with one carbon atom located at the end of the side chain.
  • Connected at two or more points means that two or more of the carbon atoms constituting the main chain are each single-bonded with two or more carbon atoms located at the end of the side chain.
  • a quaternary ammonium salt polymer has a structure having a main chain and a plurality of side chains bonded thereto.
  • the number of carbon atoms in each side chain is preferably 4 or more, more preferably 5 or more, and even more preferably 6 or more.
  • the upper limit of the carbon number is preferably 10 or less, more preferably 9 or less, and even more preferably 8 or less.
  • the number of carbon atoms in the side chain is preferably 4 or more and 10 or less, more preferably 5 or more and 9 or less, and still more preferably 6 or more and 8 or less.
  • the carbon number of the side chain is the carbon number of the quaternary ammonium moiety (cation moiety) in the side chain, and even if carbon is contained in the anion that is the counter ion, the carbon is counted. Not included.
  • the number of carbon atoms from the carbon atom bonded to the main chain to the carbon atom bonded to the quaternary nitrogen is within the aforementioned range, so that the quaternary ammonium salt. This is preferable because the steric hindrance when the polymer is adsorbed on the surface of the erythrocyte is reduced.
  • the quaternary ammonium salt polymer is a quaternary ammonium salt homopolymer
  • examples of the homopolymer include a polymer of a vinyl monomer having a quaternary ammonium moiety or a tertiary amine moiety.
  • a quaternary ammonium salt homopolymer in which the tertiary amine moiety is quaternized with an alkylating agent before and / or after polymerization are examples of the homopolymer.
  • alkylating agent and the acid are as described above.
  • the quaternary ammonium salt homopolymer preferably has a repeating unit represented by the following formula 1.
  • quaternary ammonium salt homopolymer examples include polyethyleneimine.
  • examples of the homopolymer in which the side chain having a quaternary ammonium moiety is bonded to the main chain at two or more points include polydiallyldimethylammonium chloride and polydiallylamine hydrochloride.
  • the quaternary ammonium salt polymer is a quaternary ammonium salt copolymer
  • two kinds of polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer described above are used as the copolymer.
  • a copolymer obtained by the above copolymerization can be used.
  • a quaternary ammonium salt copolymer one or more polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer described above and a polymerizable monomer having no quaternary ammonium moiety
  • the copolymer obtained by copolymerizing using 1 or more types of bodies can be used.
  • the quaternary ammonium salt copolymer can be a binary copolymer or a ternary or higher copolymer.
  • the quaternary ammonium salt copolymer has a repeating unit represented by the above-described formula 1 and a repeating unit represented by the following formula 2 to effectively produce an agglomerate of erythrocytes. It is preferable from the viewpoint.
  • a cationic polymerizable monomer an anionic polymerizable monomer, or a nonionic polymerizable monomer can be used.
  • a cationic polymerizable monomer an anionic polymerizable monomer, or a nonionic polymerizable monomer
  • charge cancellation with a quaternary ammonium moiety in a quaternary ammonium salt copolymer is achieved. Therefore, erythrocyte aggregation can be effectively generated.
  • Examples of cationic polymerizable monomers include linear compounds having a cation-carrying nitrogen atom in the main chain, such as vinylpyridine as a cyclic compound having a cation-carrying nitrogen atom under a particular condition And a condensed compound of dicyandiamide and diethylenetriamine.
  • Examples of the anionic polymerizable monomer include 2-acrylamido-2-methylpropane sulfonic acid, methacrylic acid, acrylic acid, styrene sulfonic acid, and salts of these compounds.
  • nonionic polymerizable monomers examples include vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl Examples include acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, and butyl acrylate.
  • One of these cationic polymerizable monomers, anionic polymerizable monomers, or nonionic polymerizable monomers can be used, or any two or more of them can be used in combination. Can do.
  • a quaternary ammonium salt copolymer copolymerized using a cationic polymerizable monomer, an anionic polymerizable monomer and / or a nonionic polymerizable monomer as a polymerizable monomer has a molecular weight of However, as described above, it is preferably 10 million or less, particularly 5 million or less, and particularly preferably 3 million or less (the same applies to the quaternary ammonium salt copolymer exemplified below).
  • a polymerizable monomer having a functional group capable of hydrogen bonding can also be used as the polymerizable monomer having no quaternary ammonium moiety.
  • a polymerizable monomer having no quaternary ammonium moiety When such a polymerizable monomer is used for copolymerization, and when erythrocytes are aggregated using a quaternary ammonium salt copolymer obtained therefrom, a hard aggregate is likely to be formed. Absorption performance is less likely to be disturbed.
  • the functional group capable of hydrogen bonding include —OH, —NH 2 , —CHO, —COOH, —HF, —SH and the like.
  • polymerizable monomers having functional groups capable of hydrogen bonding examples include hydroxyethyl methacrylate, vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl An acrylate etc. are mentioned.
  • hydroxyethyl methacrylate, 2-hydroxyethyl methacrylate, hydroxyethyl acrylate, dimethylacrylamide, and the like in which hydrogen bonds work strongly, are preferable because the adsorption state of quaternary ammonium salt polymers on erythrocytes is stabilized.
  • These polymerizable monomers can be used individually by 1 type or in combination of 2 or more types.
  • a polymerizable monomer having a functional group capable of hydrophobic interaction can also be used.
  • a polymerizable monomer for copolymerization By using such a polymerizable monomer for copolymerization, the same advantageous effect as that in the case of using the polymerizable monomer having a functional group capable of hydrogen bonding described above, that is, the hardness of erythrocytes The effect that it becomes easy to produce an agglomerate is produced.
  • functional groups capable of hydrophobic interaction include alkyl groups such as methyl, ethyl, and butyl groups, phenyl groups, alkylnaphthalene groups, and fluorinated alkyl groups.
  • polymerizable monomers having functional groups capable of hydrophobic interaction examples include methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, butyl acrylate, styrene, etc. Is mentioned.
  • methyl methacrylate, methyl acrylate, butyl methacrylate, butyl acrylate, etc. which have a strong hydrophobic interaction and do not significantly reduce the solubility of the quaternary ammonium salt polymer, are adsorbed to erythrocytes by the quaternary ammonium salt polymer. Is preferable because of stabilization.
  • These polymerizable monomers can be used individually by 1 type or in combination of 2 or more types.
  • the molar ratio of the polymerizable monomer having a quaternary ammonium moiety and the polymerizable monomer having no quaternary ammonium moiety in the quaternary ammonium salt copolymer is the quaternary ammonium salt. It is preferable that the red blood cells are appropriately adjusted so as to be sufficiently aggregated by the ammonium salt copolymer.
  • the molar ratio of the polymerizable monomer having a quaternary ammonium moiety in the quaternary ammonium salt copolymer is preferably 10 mol% or more, more preferably 22 mol% or more, and 32 mol. % Or more, more preferably 38 mol% or more.
  • the molar ratio of the polymerizable monomer having a quaternary ammonium moiety is preferably 10 mol% or more and 100 mol% or less, more preferably 22 mol% or more and 80 mol% or less, More preferably, it is 32 mol% or more and 65 mol% or less, and more preferably 38 mol% or more and 56 mol% or less.
  • the quaternary ammonium salt polymer is a quaternary ammonium salt polycondensate
  • a condensate composed of one or more monomers having the quaternary ammonium moiety described above is used as the polycondensate.
  • Polycondensates obtained by polymerizing these condensates can be used. Specific examples include dicyandiamide / diethylenetriamine polycondensate, dimethylamine / epichlorohydrin polycondensate, and the like.
  • the quaternary ammonium salt homopolymer and quaternary ammonium salt copolymer described above can be obtained by a homopolymerization method or a copolymerization method of a vinyl polymerizable monomer.
  • the polymerization method for example, radical polymerization, living radical polymerization, living cation polymerization, living anion polymerization, coordination polymerization, ring-opening polymerization, polycondensation and the like can be used.
  • radical polymerization, living radical polymerization, living cation polymerization, living anion polymerization, coordination polymerization, ring-opening polymerization, polycondensation and the like can be used.
  • the conditions under which a quaternary ammonium salt polymer having the desired molecular weight, streaming potential, and / or IOB value can be obtained may be appropriately selected.
  • the cationic polymer described in detail above is an example of the above-mentioned “preferable hemagglutinating agent”, and the effect thereof is Japanese Patent Application No. 2015-239286, Japanese Patent Application Laid-Open No. 2016-107100, which is a Japanese publication of the application, and Reference can be made to Examples 1 to 45 described in International Publication No. 2016/093233 pamphlet of the international application based on the priority of the application.
  • the hemagglutinating agent used in the present invention includes one third component such as a solvent, a plasticizer, a fragrance, an antibacterial / deodorant, and a skin care agent. It may be in the form of a composition (hemagglutinating agent composition) contained above.
  • a solvent water, a water-soluble organic solvent such as a saturated aliphatic monohydric alcohol having 1 to 4 carbon atoms, or a mixed solvent of the water-soluble organic solvent and water can be used.
  • the plasticizer glycerin, polyethylene glycol, propylene glycol, ethylene glycol, 1,3-butanediol and the like can be used.
  • flavor which has the green herbal-like fragrance described in patent 4776407, the extract of a plant, the extract of citrus fruits, etc.
  • an antibacterial / deodorant it is polymerized from a cancrinite-like mineral containing a metal having antibacterial properties described in Japanese Patent No. 4526271, and a polymerizable monomer having a phenyl group described in Japanese Patent No. 4587928. Porous polymers, quaternary ammonium salts, activated carbon, clay minerals and the like described in Japanese Patent No. 4651392 can be used.
  • the skin care agent plant extracts, collagen, natural moisturizing ingredients, moisturizing agents, keratin softening agents, anti-inflammatory agents and the like described in Japanese Patent No. 4084278 can be used.
  • the proportion of the cationic polymer in the hemagglutinating agent composition is preferably 1% by mass or more, more preferably 3% by mass or more, and further preferably 5% by mass or more. Further, it is preferably 50% by mass or less, more preferably 30% by mass or less, and still more preferably 10% by mass or less.
  • the pair of side leakage preventing grooves 81 is composed of the three short grooves 81a to 81c.
  • the number of short grooves 81a to 81c to be performed is not limited to three.
  • the number of the short grooves 81a to 81c constituting the side leakage preventing groove 81 is two or more, and preferably three or more.
  • the upper limit is not particularly limited, but is preferably 5 or less, more preferably 4 or less.
  • the plurality of short grooves in the side leakage prevention groove 81 may be arranged in a straight line in the vertical direction, or as a whole, the side of the shape curved in a convex shape toward the inner side in the horizontal direction Y.
  • the leak-proof groove 81 may be formed, or the side leak-proof groove 81 having a shape curved in a convex shape toward the outside in the lateral direction Y may be formed.
  • part or all of the short grooves 81a to 81c constituting the side leak-proof groove 81 do not overlap in the lateral direction Y. In addition, they may overlap in the vertical direction X.
  • the lower member containing the hemagglutinating agent may be a member other than the skin-side core wrap sheet, for example, an absorbent core or a non-skin-side core wrap sheet, and the hemagglutinating agent may be two or more lower members. It may be in a state of being contained over the entire area.
  • a hemagglutinating agent may be arranged so as to cover any two or more of the skin-side core wrap sheet, the absorbent core, and the non-skin-side core wrap sheet.
  • a hemagglutinating agent may be disposed so as to cover the entire sex core and non-skin-side core wrap sheet.
  • the absorbent core 41 is not limited to the one having a uniform thickness over the entire area in the plane direction.
  • a part of the plane direction for example, a central part of the excretory part facing part B, etc.
  • a raised portion that protrudes toward the skin side can also be formed.
  • Such a raised portion can be formed, for example, on a part of the absorbent core 41 by partially increasing the basis weight of a constituent material such as pulp fiber.
  • the absorbent article may be one that does not have a side leak-proof sheet and a leak-proof mechanism thereby, or may not have a wing portion.
  • the absorbent article of the present invention may be a sanitary napkin, a panty liner (clay sheet), or the like.
  • the present invention further discloses the following absorbent article.
  • a liquid-permeable surface sheet that forms a skin-facing surface, a back sheet that forms a non-skin-facing surface, and an absorber disposed between both sheets, and a longitudinal direction and a longitudinal direction along the front-rear direction of the wearer
  • An absorbent article for menstrual blood absorption having a lateral direction perpendicular to the skin, and having side leakage grooves on both sides of the longitudinal center line in the skin-facing surface,
  • a plurality of short grooves in which the top sheet is invaded into the absorber have a configuration arranged in the longitudinal direction so as to have a gap between the short grooves, and are positioned closer to the back sheet than the top sheet A site where the hemagglutinating agent is contained in the lower leakage member, and the gap in the side leakage preventing groove or the laterally inner side of the gap is disposed in the lower member.
  • the absorbent article according to ⁇ 1> wherein the absorbent article has a portion where the hemagglutinating agent is not disposed in a central portion in a lateral direction of the absorbent article.
  • the said lower member is an absorbent article as described in said ⁇ 1> or ⁇ 2> which is a member adjacent to the said surface sheet in the thickness direction of an absorbent article.
  • the portion of the lower member where the hemagglutinating agent is disposed has an abundance per unit area of the hemagglutinating agent in the overlapping portion overlapping the gap between the short grooves or the inner side in the lateral direction of the gap,
  • the portion of the lower member where the hemagglutinating agent is disposed has an abundance per unit area of the hemagglutinating agent in the overlapping portion overlapping the gap between the short grooves or the inner side in the lateral direction of the gap,
  • ⁇ 6> The absorbent article according to any one of ⁇ 1> to ⁇ 5>, wherein the hemagglutinating agent has a weight average molecular weight of 2,000 to 30 million.
  • the side leakage prevention groove includes a plurality of non-linear short grooves.
  • the plurality of non-linear short grooves have at least one curved portion that is convexly curved inward or outward in the lateral direction. Or an absorbent article according to claim 1.
  • ⁇ 9> Any one of ⁇ 1> to ⁇ 8>, wherein a part or all of the plurality of short grooves in the side leakage preventing groove has a shape curved in a convex shape toward the inner side in the lateral direction. Or an absorbent article according to claim 1.
  • ⁇ 10> Any one of ⁇ 1> to ⁇ 8>, wherein a part or all of the plurality of short grooves in the side leakage preventing groove has a shape curved in a convex shape outward in the lateral direction.
  • ⁇ 11> Any one of the above ⁇ 1> to ⁇ 10>, wherein a part or all of the plurality of short grooves constituting the side leakage preventing groove overlap in the vertical direction without overlapping in the horizontal direction 2.
  • the absorbent article according to 1. ⁇ 12> The absorbent body has an absorbent core and a core wrap sheet that covers the absorbent core, The absorbent article according to any one of ⁇ 1> to ⁇ 11>, wherein the lower member containing the hemagglutinating agent is the absorbent core.
  • the absorbent body has an absorbent core and a core wrap sheet that covers the absorbent core,
  • the core wrap sheet has a skin side portion covering the skin facing surface side of the absorbent core and a non-skin portion covering the non skin facing surface side of the absorbent core, and includes the hemagglutinating agent.
  • the absorbent article according to any one of ⁇ 1> to ⁇ 12>, wherein the lower member is a non-skin portion of a core wrap sheet.
  • ⁇ 14> The absorption according to any one of ⁇ 1> to ⁇ 13>, wherein the hemagglutinating agent containing the hemagglutinating agent is contained in two or more lower members. Sex goods.
  • the absorbent body has an absorbent core and a core wrap sheet that covers the absorbent core
  • the core wrap sheet has a skin side portion covering the skin facing surface side of the absorbent core, and a non-skin portion covering the non skin facing surface side of the absorbent core
  • the lower member is A skin side portion of a core wrap sheet, the absorbent core and a non-skin portion of the core wrap sheet, the core wrap sheet covering a skin facing surface side of the absorbent core;
  • the absorbent article according to any one of ⁇ 1> to ⁇ 14>, wherein an agent is disposed.
  • the absorbent body has an absorbent core and a core wrap sheet that covers the absorbent core
  • the core wrap sheet has a skin side portion covering the skin facing surface side of the absorbent core, and a non-skin portion covering the non skin facing surface side of the absorbent core
  • the lower member is A blood cell that includes the skin side portion of the core wrap sheet, the absorbent core, and the skin side portion of the core wrap sheet, and covers all of the skin side portion of the core wrap sheet, the absorbent core, and the non-skin portion of the core wrap sheet.
  • Example 1 A sanitary napkin having the form shown in FIG. 1 was prepared and used as a sample of Example 1. An uneven nonwoven fabric with a basis weight of 30 g / m 2 having ridges extending in the longitudinal direction X was used as the top sheet, and a moisture-permeable resin film was used as the back sheet. The sanitary napkin had a thickness of 4.2 mm.
  • the absorbent 4 is a mixed fiber (absorbent core) containing wood pulp fibers and a superabsorbent polymer.
  • the mixed fiber is a thin paper having a basis weight of 16 g / m 2 and a thickness of 0.3 mm. What was coated with (tissue paper) was used.
  • the mixed fiber body had a basis weight of wood pulp fibers of 300 g / m 2 and a basis weight of superabsorbent polymer of 56 g / m 2 .
  • As the superabsorbent polymer a general-purpose grade superabsorbent polymer for sanitary goods manufactured by Nippon Shokubai Co., Ltd. was used.
  • aqueous solution prepared by dissolving 5 g of the hemagglutinating agent of the following formulation in 100 g of ion-exchanged water is prepared, and this solution is a part of the core wrap sheet covering the skin facing surface of the absorbent core (skin-side core wrap sheet).
  • this solution is a part of the core wrap sheet covering the skin facing surface of the absorbent core (skin-side core wrap sheet).
  • the agent used was 12 g / m 2 .
  • Unisense FPA1002L (Senka Corporation; polydiallyldimethylammonium chloride (weight average molecular weight: 600,000)
  • Example 2 5 of the same commercially available hemagglutinating agent as in Example 1 is placed on the portion of the core wrap sheet that covers the skin facing surface of the absorbent core (skin-side core wrap sheet), which is indicated by reference numeral 9A in FIG.
  • a sanitary napkin was prepared in the same manner as in Example 1 except that a% aqueous solution was applied and dried, and this was used as the sample of Example 2.
  • Example 3 A sanitary napkin was prepared in the same manner as in Example 1 except that the application amount of the hemagglutinating agent was changed to 50 g / m 2 in terms of solid content, and this was used as a sample of Example 3.
  • Example 1 A sanitary napkin was prepared in the same manner as in Example 1 except that a hemagglutinating agent was not used and an annular leak-proof groove continuous over the entire circumference was formed as an annular leak-proof groove. One sample was used.
  • Comparative Example 2 A sanitary napkin was prepared in the same manner as in Example 1 except that no hemagglutinating agent was used, and this was used as a sample of Comparative Example 2.
  • the simulated blood is a B-type viscometer (manufactured by Toki Sangyo Co., Ltd., model number TVB-10M, measurement condition: rotor No.
  • a blood cell / plasma ratio of defibrinated horse blood (manufactured by Japan Biotest Laboratories Co., Ltd.) was prepared so that the viscosity measured using 19, 30 rpm, 25 ° C., 60 seconds) was 8 mPa ⁇ s. is there.
  • the sanitary napkin of Comparative Example 1 in which a continuous annular leak-proof groove was formed was superior in leak-proof property but inferior in flexibility and did not use a hemagglutinating agent.
  • the sanitary napkin of Example 2 has good flexibility, but poor leakage resistance.
  • the sanitary napkins of Examples 1 to 3, which are examples of the present invention are excellent in both flexibility and leakage prevention.
  • the absorbent article of the present invention is excellent in both fit and leakproofness.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
PCT/JP2017/019965 2016-06-03 2017-05-29 吸収性物品 WO2017209070A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201780018704.3A CN108883002A (zh) 2016-06-03 2017-05-29 吸收性物品

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016112125A JP6669595B2 (ja) 2016-06-03 2016-06-03 吸収性物品
JP2016-112125 2016-06-03

Publications (1)

Publication Number Publication Date
WO2017209070A1 true WO2017209070A1 (ja) 2017-12-07

Family

ID=60477818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/019965 WO2017209070A1 (ja) 2016-06-03 2017-05-29 吸収性物品

Country Status (3)

Country Link
JP (1) JP6669595B2 (zh)
CN (1) CN108883002A (zh)
WO (1) WO2017209070A1 (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57153648A (en) * 1981-02-17 1982-09-22 Kimberly Clark Co Sanitary article containing blood gelling agent
JP2002528232A (ja) * 1998-10-30 2002-09-03 キンバリー クラーク ワールドワイド インコーポレイテッド 流体処理剤を備える吸収性物品
US20030124936A1 (en) * 1998-10-30 2003-07-03 Potts David Charles Absorbent article with fluid treatment agent
JP2010148708A (ja) * 2008-12-25 2010-07-08 Uni Charm Corp 薄型吸収性物品
JP2010148719A (ja) * 2008-12-25 2010-07-08 Uni Charm Corp 吸収性物品
JP2014068991A (ja) * 2012-10-01 2014-04-21 Kao Corp 吸収性物品

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1691895A (en) * 1994-02-17 1995-09-04 Procter & Gamble Company, The Porous absorbent materials having modified surface characteristics and methods for making the same
US7928282B2 (en) * 2004-04-30 2011-04-19 Kimberly-Clark Worldwide, Inc. Absorbent products with a linked enzyme treatment
CN201227434Y (zh) * 2008-03-07 2009-04-29 大连永兴生物医药孵化器有限公司 一种用于痔疮止血的护垫
JP5349283B2 (ja) * 2009-12-25 2013-11-20 大王製紙株式会社 吸収性物品
JP5827036B2 (ja) * 2010-08-31 2015-12-02 大王製紙株式会社 吸収性物品
TWI448277B (zh) * 2011-03-31 2014-08-11 Uni Charm Corp Absorbent items
JP5717686B2 (ja) * 2012-04-02 2015-05-13 ユニ・チャーム株式会社 吸収性物品
JP6116179B2 (ja) * 2012-09-28 2017-04-19 ユニ・チャーム株式会社 吸収性物品

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57153648A (en) * 1981-02-17 1982-09-22 Kimberly Clark Co Sanitary article containing blood gelling agent
JP2002528232A (ja) * 1998-10-30 2002-09-03 キンバリー クラーク ワールドワイド インコーポレイテッド 流体処理剤を備える吸収性物品
US20030124936A1 (en) * 1998-10-30 2003-07-03 Potts David Charles Absorbent article with fluid treatment agent
JP2010148708A (ja) * 2008-12-25 2010-07-08 Uni Charm Corp 薄型吸収性物品
JP2010148719A (ja) * 2008-12-25 2010-07-08 Uni Charm Corp 吸収性物品
JP2014068991A (ja) * 2012-10-01 2014-04-21 Kao Corp 吸収性物品

Also Published As

Publication number Publication date
JP2017217103A (ja) 2017-12-14
CN108883002A (zh) 2018-11-23
JP6669595B2 (ja) 2020-03-18

Similar Documents

Publication Publication Date Title
JP2017217465A (ja) 吸収性物品
WO2017209071A1 (ja) 吸収性物品
JP6949668B2 (ja) 吸収性物品
WO2017209068A1 (ja) 吸収性物品
JP6279014B2 (ja) 吸収性物品
JP2018007705A (ja) 生理用吸収性物品
JP6259540B2 (ja) 生理用吸収性物品
JP6228629B1 (ja) 吸収性物品
JP6279015B2 (ja) 吸収性物品
JP3222476U (ja) 生理用吸収性物品
JP2017217078A (ja) 吸収性物品
JP2017217069A (ja) 生理用吸収性物品
JP2017217466A (ja) 吸収性物品
WO2017209076A1 (ja) 生理用吸収性物品
WO2017209070A1 (ja) 吸収性物品
WO2017209069A1 (ja) 吸収性物品
JP6887878B2 (ja) 吸収性物品
WO2017209074A1 (ja) 吸収性物品
JP6259539B2 (ja) 生理用吸収性物品
JP6762142B2 (ja) 吸収性物品
WO2017110716A1 (ja) 吸収性物品
JP2019041794A (ja) 吸収性物品
WO2017209073A1 (ja) 吸収性物品
JP6949662B2 (ja) 吸収性物品
WO2017209072A1 (ja) 吸収性物品

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17806625

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17806625

Country of ref document: EP

Kind code of ref document: A1